Galectin Therapeutics (GALT) Net Cash Flow Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.78% |
| Dec 31, 2025 | 25.66% |
| Sep 30, 2025 | 23.13% |
| Jun 30, 2025 | 34.93% |
| Mar 31, 2025 | -13.12% |
| Dec 31, 2024 | -33.06% |
| Sep 30, 2024 | 23.24% |
| Jun 30, 2024 | -46.14% |
| Mar 31, 2024 | -10.44% |
| Dec 31, 2023 | 36.82% |
| Sep 30, 2023 | 53.91% |
| Jun 30, 2023 | -51.93% |
| Mar 31, 2023 | -23.29% |
| Dec 31, 2022 | 22.04% |
| Sep 30, 2022 | -30.93% |
| Jun 30, 2022 | -10.46% |
| Mar 31, 2022 | -36.17% |
| Dec 31, 2021 | 44.83% |
| Sep 30, 2021 | 35.53% |
| Jun 30, 2021 | 34.19% |
| Mar 31, 2021 | -12.83% |
| Dec 31, 2020 | -26.16% |
| Sep 30, 2020 | -10.24% |
| Jun 30, 2020 | 3.04% |
| Mar 31, 2020 | -83.47% |
| Dec 31, 2019 | -6.63% |
| Sep 30, 2019 | 11.94% |
| Jun 30, 2019 | 86.83% |
| Mar 31, 2019 | -15.43% |
| Dec 31, 2018 | -34.69% |
| Sep 30, 2018 | -15.75% |
| Jun 30, 2018 | 40.07% |
| Mar 31, 2018 | 19.12% |
| Dec 31, 2017 | -18.17% |
| Sep 30, 2017 | -0.85% |
| Jun 30, 2017 | -15.64% |
| Mar 31, 2017 | -17.00% |
| Dec 31, 2016 | 14.74% |
| Sep 30, 2016 | -117.43% |
| Jun 30, 2016 | -45.08% |
| Mar 31, 2016 | -39.60% |
| Dec 31, 2015 | 8.03% |
| Sep 30, 2015 | -152.64% |